|1.||Ojima, Iwao: 5 articles (06/2015 - 07/2005)|
|2.||Gut, Ivan: 3 articles (10/2012 - 07/2005)|
|3.||Václavíková, Radka: 2 articles (10/2012 - 06/2012)|
|4.||Souček, Pavel: 2 articles (10/2012 - 06/2012)|
|5.||Horský, Stanislav: 2 articles (10/2012 - 06/2012)|
|6.||Kovář, Jan: 2 articles (10/2012 - 06/2012)|
|7.||Vobořilová, Jana: 2 articles (10/2012 - 06/2012)|
|8.||Chen, Jin: 2 articles (10/2012 - 07/2005)|
|9.||Ehrlichová, Marie: 2 articles (10/2012 - 06/2012)|
|10.||Perou, Charles M: 1 article (06/2015)|
01/01/2010 - "New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells."
06/28/2015 - "Using a q4d×4 dosing regimen, we also found that POx/SB-T-1214 significantly inhibits the growth of LCC6-MDR orthotropic tumors, outperforming commercial paclitaxel drug Taxol and Cremophor EL formulated SB-T-1214."
10/01/2012 - "This study compared cytotoxicity and effects of the cell cycle, transport and metabolism of novel taxanes SB-T-1102, SB-T-1103, SB-T-1214 and SB-T-1216, fluorinated SB-T-12851, SB-T-12852, SB-T-12853, SB-T-12854 and IDN5109 with paclitaxel in paclitaxel-sensitive (MDA-MB-435) and paclitaxel-resistant (NCI/ADR-RES) human cancer cells. "
|2.||Breast Neoplasms (Breast Cancer)
06/28/2015 - "Moreover, a selected formulation with the taxoid SB-T-1214 is about one to two orders of magnitude more active in vitro than paclitaxel in the multidrug resistant breast cancer cell line LCC6-MDR. "
07/01/2005 - "This study compared cytotoxicity and transport of paclitaxel and docetaxel with novel taxanes SB-T-1103, SB-T-1214, and SB-T-1216 in adriamycin-sensitive (MDA-MB-435) and -resistant (NCI/ADR-RES) human breast cancer cells. "
06/01/2012 - "Suppression of Abcb1 and CYP3a1 expression by SB-T-1214 and IDN5109 could partly explain their anti-lymphoma effects, but not that of SB-T-12854. "
06/01/2012 - "The greater anti-lymphoma effects of SB-T-1214 in rats corresponded to a higher bioavailability than with SB-T-12854, and lower systemic toxicity of SB-T-1214 for rats reflected its lower cytotoxicity for P388D1 cells in vitro. "
06/01/2012 - "SB-T-1214, SB-T-12854 and IDN5109 suppressed rat lymphoma more effectively than paclitaxel, SB-T-12851, SB-T-12852, SB-T-12853 or IDN5390 as well as P388D1 leukaemia cells in vitro. "
06/01/2012 - "The very effective SB-T-1214 decreased the expression of Vegf, Egf and all receptors most prominently indicating the possible supporting role of these genes in anti-lymphoma effects. "
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Epidermal Growth Factor (EGF)